Read more
This book covers the clinical usage of JAK inhibitors, which target Janus kinases and have shown promising results in the treatment of various dermatologic conditions, including atopic dermatitis, psoriasis, vitiligo, connective tissue disorders, autoimmune bullous diseases and alopecia areata. It is likely that JAK inhibitors will continue to play an important role in the management of these conditions, with clinical trials ongoing to assess their safety and efficacy in the treatment of other dermatologic disorders, such as vitiligo and hidradenitis suppurativa. However, it is important to note that JAK inhibitors can have potential side effects, including increased risk of infections, anemia and thrombosis. Therefore, careful monitoring of patients receiving JAK inhibitors is necessary to ensure their safety.
Jak Inhibitors in Dermatology represents a treatise on this novel topic and discusses that while JAK inhibitors have shown great promise in the treatment of various dermatologic conditions, further research and monitoring is necessary to fully understand their potential benefits and risks. This book is therefore of great interest for all dermatologists as a first step to understanding this novel treatment.
List of contents
History of The Jak/Stat Pathway.- Structures of Jak Inhibitors.- Basic Pharmacology and Pharmacokinetics of Jak-Stat Inhibitors.- Mechanism of Action.- Pan-Jak Inhibitors / Non-Selective Jak Inhibitors.- Selective Jak Inhibitor: Abrocitinib (Jak1-Selective).- Selective Jak Inhibitor: Ritlecitinib.- Selective Jak Inhibitor: Upadacitinib (Jak1-Selective).- Novel Jak Inhibitors.- Dermatological Indications: Atopic Dermatitis.- Dermatological Indications: Alopecia Areata.- Dermatological Indications: Psoriasis.- Dermatological Indications: Vitiligo.- Dermatological Indications: E-Other Dermatological Indications.- Topical Jak Inhibitors.- Safety, Toxicity Profile, and Side Effects.- Jak Inhibitors/Drug Interactions.- Use of Jak Inhibitors in Dermatology Under Special Conditions.- The Future of Jak Inhibitors in Dermatology.- Conclusion.- Index.
About the author
Umit Türsen graduated from Gazi University Faculty of Medicine as Medical Doctor. He completed the residency period of Dermatology in Ankara University, Faculty of Medicine, and Department of Dermatology between 1995-1999. He has been working in Mersin University, School of Medicine, and Department of Dermatology since 2000. He is the Professor of Mersin University, School of Medicine, and Dermatology Department. He has published more than 80 papers in reputed journals, also books and serving as an editorial board member of repute. He won Behcet’s disease research award of “The scientific and technical research council of Turkey (TUBITAK)” in 1999. He is married and he has 2 children. He is president of INDERCOS Congress and also Mersin Dermatology and Cosmetology Association.
Prof Dr Ayşe Serap Karadağ graduated from Gazi University Faculty of Medicine in 1999. She completed my specialization training in S.B.Ankara Training and Research Hospital, Dermatology and Venereal Diseases Clinic and worked as a specialist doctor in Kırşehir State Hospital, Keçiören Training and Research Hospitals for 5 years. She worked at Yüzüncü Yıl University Faculty of Medicine between 2010-2012, and at Istanbul Medeniyet University Faculty of Medicine between 2012-2020 as an academician, lecturer and educator. She served as the Head of the Department between 2012-2013, the Head of the Clinical Research Ethics Committee in 2014-2015, and the Secretary of the Turkish Dermatology Association (TDD) Acne Study Group between 2012-2018. She is still a member of TDD Acne Study Group Presidency, TDD Accreditation Board, DUSEK Post-Specialist Training Commission and Dermatology Proficiency Exam Commission, which I was appointed in 2018. Between 2015-2016, she participated as an observer in the academic programs of Thomas Jefferson University, UPEN and Cooper Universities in the USA. In 2016, she was at the Benedetto Dermatosurgery clinic in Philadelphia for 3 months.
Summary
This book covers the clinical usage of JAK inhibitors, which target Janus kinases and have shown promising results in the treatment of various dermatologic conditions, including atopic dermatitis, psoriasis, vitiligo, connective tissue disorders, autoimmune bullous diseases and alopecia areata. It is likely that JAK inhibitors will continue to play an important role in the management of these conditions, with clinical trials ongoing to assess their safety and efficacy in the treatment of other dermatologic disorders, such as vitiligo and hidradenitis suppurativa. However, it is important to note that JAK inhibitors can have potential side effects, including increased risk of infections, anemia and thrombosis. Therefore, careful monitoring of patients receiving JAK inhibitors is necessary to ensure their safety.
Jak Inhibitors in Dermatology represents a treatise on this novel topic and discusses that while JAK inhibitors have shown great promise in the treatment of various dermatologic conditions, further research and monitoring is necessary to fully understand their potential benefits and risks. This book is therefore of great interest for all dermatologists as a first step to understanding this novel treatment.
